Cardio-oncology is a specialized area of cardiology focused on protecting the heart health of people undergoing cancer treatment and cancer survivors — since certain chemotherapy drugs, targeted therapies, and radiation can affect the heart, both during treatment and, sometimes, years later. The goal is never to prevent you from getting the cancer treatment you need — it's to monitor and manage your heart alongside it, so cancer treatment and heart health don't have to be in conflict.
What Is Cardio-Oncology?
A collaborative field where cardiologists work closely with oncologists to monitor for and manage cardiovascular effects of cancer therapies — before treatment starts, during treatment, and in long-term survivorship — so that effective cancer treatment can proceed as safely as possible for your heart.
What's Happening in Your Heart
Different cancer therapies can affect the heart through different mechanisms: some directly weaken heart muscle cells (a variety of chemotherapy and targeted agents), some raise blood pressure or clotting risk, some affect heart rhythm, and radiation to the chest can affect heart valves, arteries, and the sac around the heart, sometimes appearing years after treatment ends. Your specific risk depends heavily on which therapies you're receiving, your baseline heart health, and other risk factors.
Types & Causes
- Anthracyclines (a chemotherapy class) — can weaken heart muscle, with risk related to cumulative dose over a lifetime, which is why your oncology team tracks your total lifetime exposure to this class carefully, even across different treatment courses over the years
- HER2-targeted therapies — can affect heart function, usually reversible but requiring monitoring during treatment, and requiring extra caution when combined with anthracyclines, since the two together raise risk more than either alone
- Radiation to the chest — can affect heart valves, coronary arteries, and the pericardium (the sac around the heart), sometimes with effects appearing years to decades later
- Immune checkpoint inhibitors — a newer and increasingly used class of immunotherapy that can, uncommonly but seriously, cause immune-related heart inflammation (myocarditis); this is rare but can be severe, so new chest symptoms, palpitations, or unusual fatigue during treatment with these agents deserve prompt evaluation
- Other targeted therapies — a growing list of newer cancer drugs with their own specific cardiovascular monitoring needs, including effects on blood pressure, heart rhythm, and clotting risk
- Baseline cardiovascular risk factors (hypertension, prior heart disease, age) compound the risk from cancer therapy itself
Common Symptoms
Can be silent, detected only through monitoring — or can include shortness of breath, fatigue, swelling, chest pain, palpitations, or a new irregular heartbeat during or after cancer treatment.
How It's Diagnosed
A baseline cardiac evaluation is often recommended before starting a heart-affecting cancer therapy, including an echocardiogram and sometimes specific blood markers (like troponin or NT-proBNP, which can flag early heart strain before symptoms or a drop in EF appear). Ongoing monitoring during treatment tracks for early changes in heart function, often with echocardiograms at defined intervals tailored to your specific therapy and risk level. Cardiac MRI can add detail when echo findings are unclear. (See Cardiac Testing & Imaging.)
Main Treatment Options
When heart function changes are detected, standard heart failure medications are often started proactively — sometimes even continuing your cancer treatment alongside them, rather than automatically stopping effective cancer therapy. The specific approach is always a coordinated decision between your cardio-oncology team and your oncologist, weighing your cancer treatment goals against your cardiovascular risk. For radiation-related valve or artery disease showing up years later, standard treatments for those specific conditions apply.
Lifestyle Changes That Help
- Attending every scheduled cardiac monitoring appointment during cancer treatment, even if you feel completely well
- Standard cardiovascular risk factor control (blood pressure, cholesterol, blood sugar, smoking cessation) — these compound with cancer-therapy risk, so controlling them matters more, not less, during cancer treatment
- Long-term cardiac follow-up after treatment ends, especially after chest radiation or anthracycline chemotherapy, since some effects can emerge years later
- Open communication between your oncology and cardiology teams — ask that they're coordinating directly, not just through you
Living With It
For most people, cancer treatment and heart health can be successfully managed together, and cardiac monitoring allows most patients to complete their planned cancer therapy. Long-term cancer survivors — particularly those who had chest radiation or certain chemotherapy classes — benefit from ongoing cardiovascular awareness for years after treatment ends, since this is a genuinely lifelong consideration for some therapy types, not just a concern during active treatment. Many cancer centers now have formal survivorship programs that include structured, long-term cardiac follow-up specifically for this reason.
When to Call Your Doctor vs. Go to the ER
- New shortness of breath, fatigue, or swelling during or after cancer treatment
- New palpitations
- Chest pain, severe shortness of breath, or fainting
Common Questions
Will seeing a cardiologist delay my cancer treatment?
Usually not — the goal of cardio-oncology is specifically to help you safely continue effective cancer treatment, with monitoring built in alongside it rather than treatment being paused unnecessarily.
I finished cancer treatment years ago — why does my oncologist want me to see a cardiologist now?
Because some cardiovascular effects of certain therapies (particularly chest radiation and certain chemotherapy) can emerge years to decades later — long-term survivorship monitoring is a recognized, important part of cancer survivorship care.
Does having cancer automatically mean I'll have heart problems?
No — many people complete cancer treatment with no lasting cardiac effects; monitoring exists specifically to catch and address the subset of people who do develop them, as early as possible.
What baseline testing is typical before starting a cardiotoxic cancer treatment?
Commonly a baseline echocardiogram to measure your starting ejection fraction, sometimes with additional bloodwork — this gives your cardio-oncology team a personal comparison point for any future testing, rather than relying on general population norms alone.
I'm on an immunotherapy drug — what heart symptoms should worry me?
New chest pain, palpitations, unusual shortness of breath, or profound unexplained fatigue during treatment deserve prompt evaluation, since immune-related heart inflammation, while rare, can progress quickly — don't wait for your next scheduled visit if something feels new or wrong.
Does my cardio-oncologist talk directly to my oncologist?
Ideally yes, and it's reasonable to ask that they do — coordinated care between the two teams, rather than information relayed only through you, is the model most cardio-oncology programs are built around.